These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16681698)

  • 1. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
    Galloway ML; Murray D; Moffat DF
    Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.
    Kao SC; Griggs K; Lee K; Armstrong N; Clarke S; Vardy J; van Zandwijk N; Burn J; McCaughan BC; Henderson DW; Klebe S
    Pathology; 2011 Jun; 43(4):313-7. PubMed ID: 21532523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
    Pu RT; Pang Y; Michael CW
    Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
    Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
    Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical comparison of diffuse malignant mesothelioma of the pleura and pseudomesotheliomatous carcinoma of the lung for each case].
    Yuasa H; Tomoyasu M
    Kyobu Geka; 1999 Sep; 52(10):836-9. PubMed ID: 10478545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
    Deniz H; Kibar Y; Güldür ME; Bakir K
    Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
    Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
    Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
    Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
    Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural mesothelioma in situ and its adenocarcinoma simulator.
    Bono F
    Int J Surg Pathol; 2010 Dec; 18(6):519-20. PubMed ID: 21081535
    [No Abstract]   [Full Text] [Related]  

  • 14. CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry.
    Kawamura K; Hiroshima K; Suzuki T; Chai K; Yamaguchi N; Shingyoji M; Yusa T; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Oct; 140(4):544-9. PubMed ID: 24045552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
    Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
    Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
    Attanoos RL; Gibbs AR
    Histopathology; 2008 Sep; 53(3):340-4. PubMed ID: 18647189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant fibrous mesothelioma and granulomas].
    Esquirol Puig X; Vilaseca Bellsolà J; Pujol Ribó J
    Med Clin (Barc); 1989 Feb; 92(5):198. PubMed ID: 2725108
    [No Abstract]   [Full Text] [Related]  

  • 20. [Large-cell carcinoma presenting as diffuse thickening of the pleura and resembling malignant mesothelioma].
    Nakamura H; Ikeda I; Nakahama H; Kitada O; Sugita M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Apr; 35(4):451-4. PubMed ID: 9212673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.